CALIFORNIA | LOCAL
February 25, 1990 |
This year, about 500,000 Americans will develop skin cancer. Most will have a highly curable form, but 27,000 people will be diagnosed with a potentially deadly type known as melanoma. For melanoma sufferers, doctors say the best hope for long-term survival is early diagnosis. A new study suggests that a free nationwide screening program begun in 1975 can be highly effective in detecting melanoma and other skin cancers at an early stage.
March 26, 2011 |
The Food and Drug Administration on Friday bolstered the skimpy pharmaceutical arsenal against late-stage melanoma by approving Yervoy, the first drug shown to extend the lives of patients with the deadly skin cancer. The drug, marketed by Bristol-Myers Squibb Co. of Princeton, N.J., is the first FDA-approved treatment for metastatic melanoma in 13 years and has triggered particular interest among oncologists because there are indications that, in addition to prolonging some patients' lives, it may cure others.
CALIFORNIA | LOCAL
April 19, 1990 |
A drug developed at Scripps Research Institute has shown near-total effectiveness against a rare form of leukemia without the debilitating side effects that usually accompany cancer therapy, San Diego researchers say. Reporting in today's issue of the New England Journal of Medicine, the Scripps scientists were careful to point out that the cancer they studied, hairy-cell leukemia, is diagnosed in only 500 to 600 people a year in the United States.
February 5, 2002 |
Sen. John McCain (R-Ariz.) underwent successful surgery Monday night to remove a small melanoma from his nose, a spokesman said. Surgeons at the Mayo Clinic Hospital in Phoenix took about an hour to remove a skin lesion less than one centimeter in size from the left side of McCain's nose that was considered to be "the earliest form of melanoma," the statement said. He received a local anesthetic.
April 15, 1997
Chiron Corp. said it filed for U.S. approval to sell Proleukin, its drug for kidney cancer, as a treatment for advanced melanoma. Proleukin received Orphan Drug status from the Food and Drug Administration last September for treating metastatic, or advanced, melanoma. The status encourages companies to develop new treatments for relatively rare diseases by giving them additional years of marketing exclusivity.
December 22, 1988 |
A new form of cancer immunotherapy may result in a more potent and potentially less toxic treatment for patients with advanced melanoma, a type of skin cancer that can spread throughout the body, government researchers say. Dr. Steven A. Rosenberg and his colleagues at the National Cancer Institute in Bethesda, Md.
CALIFORNIA | LOCAL
April 5, 1985 |
Actor Dan Haggerty, best known as television's Grizzly Adams, was sentenced Thursday to 90 days in County Jail and three years' probation for furnishing cocaine to two undercover police officers last year. However, Los Angeles Superior Court Judge Aurelio Munoz allowed Haggerty, 41, to remain free pending appeal of his conviction. In a split verdict last month, a jury found Haggerty guilty on one count but found that the officers entrapped him into selling them the drug on the second occasion.
October 15, 1995 |
An abnormally high incidence of malignant melanoma has been found in children around the Lawrence Livermore National Laboratory, according to California health officials. A 30-year government-sponsored cancer watch around the lab found eight cases of the deadly skin cancer among children born in the area and 12 cases among young residents born elsewhere, "a significantly elevated incidence" of the rare disease. That was far beyond the normal incidence of 1.
June 6, 2011 |
Whenever there’s an advance in the fight against cancer, there’s going to be some real excitement. And, if history is a judge, there’s going to be some disappointment, too. Treatments that look promising in the lab can fizzle in human trials. And even drugs that seem to work well in human studies may not end up helping many patients in the real world. A new study showing that the chemotherapy drug vemurafenib can prolong the lives of people with malignant melanoma — the especially aggressive and dangerous form of skin cancer that kills about 8,700 Americans each year — has rightfully lifted the spirits of doctors and patients alike.
August 26, 2010
An experimental anticancer drug that targets a specific genetic mutation benefits 80% of patients with metastatic melanoma, although in some cases the benefit was short-lived, researchers said Wednesday. The results came in a relatively small Phase II clinical trial, and testing will now proceed to a larger Phase III trial to gain approval for marketing the drug, called PLX4032. Researchers hope the drug might also provide benefits for some other types of tumors that share the same genetic defect.